SATELLOS Bioscience Announces 2023 Q3 Financial Results and Operational Highlights
Company disclosed drug target for Duchenne program; remains on track to initiate clinical trials mid-2024
SATELLOS to Present at the Piper Sandler 35th Annual Healthcare Conference
TORONTO, November 20, 2023 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB:
SATELLOS Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program
The drug target for the Duchenne program is AAK1, a protein kinase in the Notch
SATELLOS to Present at the Stifel 2023 Healthcare Conference
TORONTO, November 2, 2023 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB:
SATELLOS to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
TORONTO, September 20, 2023 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB:
SATELLOS Enters into an Agreement with ICP Securities Inc. to Provide Market Marking Services
TORONTO, September 7, 2023 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB:
SATELLOS Expands Leadership Team with New CFO Appointment
Elizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy
SATELLOS Announces Q2 2023 Financial Results and Operational Highlights
$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to
SATELLOS Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy
Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the
SATELLOS Announces Results From its Annual General Meeting of Shareholders and Adoption of Amendments to Stock Option Plan
TORONTO, June 30, 2023 – Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a